Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

Core Insights - Modus Therapeutics has received regulatory approval to initiate the second part of its phase 2 study for sevuparin, targeting chronic kidney disease with anemia, set to begin in Q4 2025 [1][2][3] Company Overview - Karolinska Development AB holds a 54% direct and 1% indirect ownership in Modus Therapeutics, indicating a significant stake in the company's progress [3] - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to develop these into commercial products that improve patient lives while providing returns to shareholders [4][5] Clinical Development - The second part of the clinical study will evaluate three doses of sevuparin, building on initial data that demonstrated the drug's good tolerance [2] - The approval is seen as a crucial milestone for Modus Therapeutics, allowing it to adhere to its planned clinical development timeline [3]